Insider Selling: Boston Scientific Corporation (NYSE:BSX) EVP Sells 15,835 Shares of Stock

Boston Scientific Corporation (NYSE:BSX) EVP Michael P. Phalen sold 15,835 shares of Boston Scientific stock in a transaction on Saturday, December 29th. The stock was sold at an average price of $25.25, for a total transaction of $399,833.75. The sale was disclosed in a document filed with the SEC, which is available at this link.

Michael P. Phalen also recently made the following trade(s):

  • On Wednesday, November 29th, Michael P. Phalen sold 15,500 shares of Boston Scientific stock. The shares were sold at an average price of $26.66, for a total transaction of $413,230.00.
  • On Monday, October 30th, Michael P. Phalen sold 15,500 shares of Boston Scientific stock. The shares were sold at an average price of $28.42, for a total transaction of $440,510.00.

Shares of Boston Scientific Corporation (BSX) traded down $0.44 during trading on Thursday, hitting $27.52. 13,011,000 shares of the stock were exchanged, compared to its average volume of 12,794,057. Boston Scientific Corporation has a twelve month low of $22.94 and a twelve month high of $29.93. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $37,630.00, a price-to-earnings ratio of 45.11, a price-to-earnings-growth ratio of 1.82 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the business posted $0.27 earnings per share. The business’s revenue was up 5.6% compared to the same quarter last year. equities analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year.

A number of research analysts have commented on BSX shares. BMO Capital Markets lifted their price objective on shares of Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Stifel Nicolaus restated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research note on Monday, September 25th. SunTrust Banks set a $33.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a research note on Monday, December 4th. Zacks Investment Research upgraded shares of Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Friday, October 20th. Finally, Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $31.00.

Several institutional investors have recently modified their holdings of BSX. Valeo Financial Advisors LLC purchased a new stake in Boston Scientific during the third quarter worth about $138,000. Steward Partners Investment Advisory LLC purchased a new stake in Boston Scientific during the third quarter worth about $139,000. Acrospire Investment Management LLC boosted its holdings in Boston Scientific by 157.3% during the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after buying an additional 3,100 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in Boston Scientific by 14.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after buying an additional 720 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA purchased a new stake in Boston Scientific during the second quarter worth about $191,000. Institutional investors and hedge funds own 90.36% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/01/11/boston-scientific-corporation-bsx-evp-michael-p-phalen-sells-15835-shares-of-stock.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply